BIO INVESTOR FORUM PRESENTATION

Transcription

1 TSX-V: TBP OTC: TBPMF BIO INVESTOR FORUM PRESENTATION Bob Béchard VP Business Development 17 OCTOBRE 2017

2 Forward Looking Statements This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the expectations and projections of Tetra Bio-Pharma Inc. The information contained in this presentation has not been approved or disapproved by any Securities Commission in Canada, The Securities and Exchange Commission in the US or other regulatory body. Except for statements of historical fact relating to the Company, certaininformation contained herein constitutes "forward-lookingstatements". Forward-lookingstatements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the inherent risks involved in the development of botanical based pharmaceuticals or medical devices regulated by Health Canada, the FDA or other international regulatory agencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated with product approvals in multiple jurisdictions. The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not to place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiencyor completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or from omissions from the information inthis presentation. 2

3 From Start-Up to Explosive Growth Tetra Bio-Pharma is focused on becoming THE Bio-Pharmaceutical leader in cannabinoid-based drug discovery & development, with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers Tetra Founded 2015 TSX-V (TBP) OTCQB (TBPMF) Market Capitalization Shares Issued Shares Fully Diluted CAD$0.73 US$0.52 US$74MM 118.8MM 132.5MM Insider Ownership 9.4% Cash/Equivalent (As of Sept 1st, 2017) G&A cash Burn Rate/Month CAD$2.2M CAD$100K 2

4 Global Leader in Cannabinoid-based Drug Discovery RESEARCH Pharmaceutical research & development of cannabinoid-based drugs PHARMACEUTICAL Commercialization of medical cannabis under ACMPR and cannabinoid-based prescription drugs RETAIL Commercialization of cannabinoid-based products for the natural health product market (self-care) 3

5 REPORT: The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020 Viridian Capital Advisors Wednesday, 02 December :43 (EST) 5

6 Why Cannabis/Cannabinoids? Tremendous Amount of Anecdotal Evidence That it Works in Chronic Pain, PTSD, Chemo Induced Nausea and Vomiting, MS, Epilepsy etc. American Academies of Science Stated There is Substantial Evidence Supporting its Use in Chronic Pain, Chemo Induced Nausea & Vomiting and MS 1/3 of Americans suffer from Chronic Pain 1/3 of US Chronic Pain Sufferers Use Opioids There is Tremendous Potential for Opioid Sparing Potential For Treating Addictions 6

7 What Makes Tetra BP an Exciting Investment? Providing pharmaceutical relevance through clinical support for cannabinoidbased drugs to treat a variety of human and veterinary diseases Developing clinically supported medical cannabis Robust Pipeline Using Multiple Forms of Delivery on a Variety of Indications Predicted cannabis-based drugs will replace drugs with toxic side effect profiles (i.e. opioids) Tremendous Amount of Anecdotal Evidence.Cannabinoids do work! Not the same investment risk as a new chemical entity 7

8 Pharmaceutical Tetra s Product Pipeline 8

9 PPP001 Prescription Dried Cannabis First smokable cannabis for advanced cancer pain Aphria: API & Strategic Partner Successfully completed Phase I Preparing launch Phase III clinical trial Q4/17 Signing commercial partner Q4/18 Anticipated filing of NDA Q4/18 Market Potential N.A.: 4M cancer patients & pain market $5 billion according to Global Pain Management 9

10 PPP002 Dronabinol XL Tablet Buccally absorbed muco-adhesive tablet Advantage over approved synthetic THC: Sustained THC release, reducing side effects and increasing drug stability Phase I completed: Safety significantly superior Human indications Chemo Induced Nausea and Vomiting and pain market Next Steps: Phase II Q1/18 Phase III Q1/19 Commercial Partnership Q1/19 Anticipated filing of NDA

11 PPP003 Ophthalmic Drugs THC:CBD containing eye drops to treat ocular pain and inflammation, uveitis and dry eye Pre-clinical proof of concept studies completed Non-clinical safety testing phase First target indication: corneal pain and inflammation Next Steps: CTA filing of Phase I trial Q2/18 Anticipated filing of NDA 2022 Partnership by Q Potential USA Market: $3 billion includes post-op inflammation and allergic conjunctivitis according to IMS 11

12 PPP004 Topical Ointment THC:CBD 1:1 topical cream to treat general neuropathic pain Pre-clinical studies underway Next Steps: CTA filing for Phase I trial Q Anticipated filing of NDA 2022 Partnership signed by 2020 Potential USA Market: $2.5 billion in 2014, over the counter sales of topical analgesics according to IMS 12

13 Business Model Typical Biotech Business Model (RX) Actively Seeking Commercialization and Development Partners Upfronts, Milestones and Royalties Our Expertise remains in Finding and Developing Cannabinoid Based Products, as well as on finding the most Efficient Regulatory Pathway to Approval by Regulatory Agencies Retail Arm used for Selling Cannabinoid Based Self-Care Products Will also begin Selling Medicinal Cannabis under CDN Compassionate Use Program 13

14 Retail Natural Health Products LOI announced July 19, 2017 with Constance Therapeutics for specialized medical cannabis products Munchies B Gone gum Pain Gel Non-greasy penetrating relief gel Sleep Pro Sleep aid for cases of restlessness /nervousness Vitally Stress ADO Used for anxiety, insomnia, dyssomnia Vitally Water Relax Used for anxiety/ tension after acute administration 14

15 Partners TBP launched a Health Research Chair in Cannabis at UNB Collaboration on study to develop consumer products containing cannabinoids Granted TBP with research funding to collaborate w Mc Gill Our partner for PPP001 production- Producer of Medicinal Cannabis Stage 1 clinical trial - PPP001 QC first medical clinic and resource centre specializing in medical cannabis. Will perform Phase 3 clinical trials of PPP001 15

16 Competitive Landscape GW Pharma $GWPH Market Capitalization: $2.7B USD GW Pharma has 2 products in its pipe line in stage 1 and stage 3 for epilepsy and MS - one approved product INSYS Therapeutics $INSY Market Capitalization: $549MM USD Is a traditional Pharma company that was awarded orphan drug status for CBD for treatment of GBM -no products in Clinical Testing Cara Therapeutics $CARA Market Capitalization: $406M USD R&D on Cannabinoid receptors. Utilizing synthetic compounds Zynerba Pharmaceuticals $ZYNE Market Capitalization: $133MM USD Developing a synthetic THC transdermal patch as well as a synthetic CBD gel Kalytera Therapeutics $KALY Market Capitalization: $17M MCAD Preparing for a Phase 2 study to evaluate cannabidiol for the prevention of GvHD 16

17 Experienced Management Team Bernard Fortier, MBA CEO Experienced in management & business development in the biopharma, specialized medical nutrition & medical fields Spent 8 years in commercial roles at Serono CAN including National Sales Manager in Neurology business unit Previous head of Orimed Pharma grew product development from 3 to 10 products within 4 years Guy Chamberland CSO Holds a M.Sc. and Ph.D. degrees, is a Master Herbalist Served as VP of Clinical & Regulatory Affairs at Victhom Laboratory. Previous VP of Regulatory Affairs & Clinical Development at Angiogene Inc Worked for CATO Research Ltd and MDS Pharma Services specializing in regulatory affairs in areas of drugs, biologics, medical devices, combination products and botanicals Bernard Lessard CFO Considerable experience as c-suite executive in life sciences sector in start-ups Involved with numerous financings, venture capital funds & M&A transactions Experienced CFO in risk management & governance Strong political connections to Quebec Government Holds a MBA, CPA, CMA Denis Courchesne VP, Sales 25 years sales and management experience in the retail environment working for various companies such as Evian Spring Water (Danone) and Pfizer Last 15 years, has workied in both the pharmacy and health food channels where he successfully held positions in Quebec as National Sales Manager Bob Bechard VP, Finance & BD 12-year term at RBC as a senior venture capitalist, he made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies Anne-Sophie Courtois VP, Marketing & communication 10 years international experience in pharmaceutical marketing Previous Director of Marketing & Scientific Affairs at Jamp Pharma & Orimed Pharma grew sales 150% in 4 years Managed marketing launch of 120 generic products & 10 branded products in Canada Is a veterinary doctor 17

18 Strong Board of Directors Andre Rancourt Chairman & Director Highly experienced in management, start-up & commercial strategies for many fields including human & animal natural health products Bernard Fortier CEO of Tetra BioPharma Robert Brouillette Bareau du Quebec, LL.B., B.Sc.A. - Director Currently Partner at Brouillette & Partners. He is a specialized lawyer, civil engineer, patent & trade-mark agent Bill Cheliak - Ph.D. - Director Currently CEO of Panag Pharma, a Canadian bio-tech focused on the development of novel cannabinoid based formulations for the treatment of pain & inflammation Carl Merton - CA, CPA, FCBV Director Currently CFO of Aphria, one of Canada s lowest cost producers, produces, supplies and sells medical cannabis 18

19 Upcoming Milestones Building Tetra as the global leader in cannabinoid-based drug discovery and development PPP001 Start Ph III study Q PPP002 Start Ph II study Q PPP003 Start Ph I study Q PPP004 Start Ph I study Q PPP001 Commercial partnership Q Focused on accelerated execution & committed to building shareholder value 19

20 Contact Anne-Sophie Courtois VP, Marketing & Communication ext

21